|
US3720760A
(en)
|
1968-09-06 |
1973-03-13 |
Pharmacia Ab |
Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
DE3378250D1
(en)
|
1982-04-22 |
1988-11-24 |
Ici Plc |
Continuous release formulations
|
|
NZ207394A
(en)
|
1983-03-08 |
1987-03-06 |
Commw Serum Lab Commission |
Detecting or determining sequence of amino acids
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
US5128326A
(en)
|
1984-12-06 |
1992-07-07 |
Biomatrix, Inc. |
Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
|
|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
|
DE3675588D1
(de)
|
1985-06-19 |
1990-12-20 |
Ajinomoto Kk |
Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
AU600575B2
(en)
|
1987-03-18 |
1990-08-16 |
Sb2, Inc. |
Altered antibodies
|
|
US5258498A
(en)
|
1987-05-21 |
1993-11-02 |
Creative Biomolecules, Inc. |
Polypeptide linkers for production of biosynthetic proteins
|
|
DE3856559T2
(de)
|
1987-05-21 |
2004-04-29 |
Micromet Ag |
Multifunktionelle Proteine mit vorbestimmter Zielsetzung
|
|
US5336603A
(en)
|
1987-10-02 |
1994-08-09 |
Genentech, Inc. |
CD4 adheson variants
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
KR900005995A
(ko)
|
1988-10-31 |
1990-05-07 |
우메모또 요시마사 |
변형 인터류킨-2 및 그의 제조방법
|
|
EP0394827A1
(en)
|
1989-04-26 |
1990-10-31 |
F. Hoffmann-La Roche Ag |
Chimaeric CD4-immunoglobulin polypeptides
|
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
|
WO1991005548A1
(en)
|
1989-10-10 |
1991-05-02 |
Pitman-Moore, Inc. |
Sustained release composition for macromolecular proteins
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
WO1991006570A1
(en)
|
1989-10-25 |
1991-05-16 |
The University Of Melbourne |
HYBRID Fc RECEPTOR MOLECULES
|
|
EP0550436A1
(en)
|
1989-11-06 |
1993-07-14 |
Alkermes Controlled Therapeutics, Inc. |
Protein microspheres and methods of using them
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5349053A
(en)
|
1990-06-01 |
1994-09-20 |
Protein Design Labs, Inc. |
Chimeric ligand/immunoglobulin molecules and their uses
|
|
DK0564531T3
(da)
|
1990-12-03 |
1998-09-28 |
Genentech Inc |
Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber
|
|
KR100246529B1
(ko)
|
1990-12-14 |
2000-04-01 |
스티븐 에이. 서윈. 엠.디. |
수용체 관련된 신호 변환 경로를 위한 키메라 사슬
|
|
US5571894A
(en)
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
CA2103059C
(en)
|
1991-06-14 |
2005-03-22 |
Paul J. Carter |
Method for making humanized antibodies
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
|
JP3540315B2
(ja)
|
1991-09-23 |
2004-07-07 |
メディカル リサーチ カウンシル |
キメラ抗体の製造−組合せアプローチ
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
NL9101953A
(nl)
|
1991-11-21 |
1993-06-16 |
Seed Capital Investments |
Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
|
|
AU3178993A
(en)
|
1991-11-25 |
1993-06-28 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
US5869619A
(en)
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
|
EP0571613B1
(en)
|
1991-12-13 |
2003-09-17 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
EP1514934B1
(en)
|
1992-02-06 |
2008-12-31 |
Novartis Vaccines and Diagnostics, Inc. |
Biosynthetic binding protein for cancer marker
|
|
US5912015A
(en)
|
1992-03-12 |
1999-06-15 |
Alkermes Controlled Therapeutics, Inc. |
Modulated release from biocompatible polymers
|
|
US5447851B1
(en)
|
1992-04-02 |
1999-07-06 |
Univ Texas System Board Of |
Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
|
|
JP3720353B2
(ja)
|
1992-12-04 |
2005-11-24 |
メディカル リサーチ カウンシル |
多価および多重特異性の結合タンパク質、それらの製造および使用
|
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
|
US5605793A
(en)
|
1994-02-17 |
1997-02-25 |
Affymax Technologies N.V. |
Methods for in vitro recombination
|
|
US5834252A
(en)
|
1995-04-18 |
1998-11-10 |
Glaxo Group Limited |
End-complementary polymerase reaction
|
|
US5837458A
(en)
|
1994-02-17 |
1998-11-17 |
Maxygen, Inc. |
Methods and compositions for cellular and metabolic engineering
|
|
GB9415379D0
(en)
|
1994-07-29 |
1994-09-21 |
Smithkline Beecham Plc |
Novel compounds
|
|
NZ292124A
(en)
|
1994-07-29 |
1998-10-28 |
Smithkline Beecham Plc |
Il-4 antagonist comprising a fusion of a mutant il-4-antibody fragment
|
|
AU4755696A
(en)
|
1995-01-05 |
1996-07-24 |
Board Of Regents Acting For And On Behalf Of The University Of Michigan, The |
Surface-modified nanoparticles and method of making and using same
|
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
EP1323346B1
(en)
|
1995-01-17 |
2006-06-28 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
EP0850051A2
(en)
|
1995-08-31 |
1998-07-01 |
Alkermes Controlled Therapeutics, Inc. |
Composition for sustained release of an agent
|
|
US5723125A
(en)
|
1995-12-28 |
1998-03-03 |
Tanox Biosystems, Inc. |
Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
|
|
WO1997033899A1
(en)
|
1996-03-14 |
1997-09-18 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule i
|
|
WO1997034631A1
(en)
|
1996-03-18 |
1997-09-25 |
Board Of Regents, The University Of Texas System |
Immunoglobin-like domains with increased half lives
|
|
KR20030096450A
(ko)
|
1996-03-22 |
2003-12-31 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
고사 유도 분자 ⅱ
|
|
EP0945506B1
(en)
|
1996-12-26 |
2007-02-28 |
Kyowa Hakko Kogyo Co., Ltd. |
Proteine avec une activite de suppression du vieillissement
|
|
GB9701425D0
(en)
|
1997-01-24 |
1997-03-12 |
Bioinvent Int Ab |
A method for in vitro molecular evolution of protein function
|
|
US20060246540A1
(en)
|
1997-08-26 |
2006-11-02 |
Ashkenazi Avi J |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US20020012961A1
(en)
|
1999-04-15 |
2002-01-31 |
Genentech, Inc. |
Fibroblast growth factor- 19
|
|
US20020042367A1
(en)
|
1997-11-25 |
2002-04-11 |
Genentech, Inc. |
Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
|
|
KR100502596B1
(ko)
|
1997-09-17 |
2005-07-22 |
제넨테크, 인크. |
분비 폴리펩티드와 막횡단 폴리펩티드 및 이들을 코딩하는핵산
|
|
US20030113718A1
(en)
|
1997-09-17 |
2003-06-19 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US6806352B2
(en)
|
1997-09-17 |
2004-10-19 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US20030044839A1
(en)
|
1997-09-17 |
2003-03-06 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US5989463A
(en)
|
1997-09-24 |
1999-11-23 |
Alkermes Controlled Therapeutics, Inc. |
Methods for fabricating polymer-based controlled release devices
|
|
SE512663C2
(sv)
|
1997-10-23 |
2000-04-17 |
Biogram Ab |
Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
|
|
ES2303358T3
(es)
|
1997-11-03 |
2008-08-01 |
Human Genome Sciences, Inc. |
Vegi, un inhibidor de la angiogenesis y el crecimiento tumoral.
|
|
US20020155543A1
(en)
|
1997-11-25 |
2002-10-24 |
Genentech, Inc. |
Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
|
|
US20040126852A1
(en)
|
1997-11-25 |
2004-07-01 |
Genentech, Inc. |
Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
|
|
US20050026832A1
(en)
|
1997-11-25 |
2005-02-03 |
Genentech, Inc. |
Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
|
|
CA2323757C
(en)
|
1998-04-02 |
2011-08-02 |
Genentech, Inc. |
Antibody variants and fragments thereof
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
HUP0104865A3
(en)
|
1999-01-15 |
2004-07-28 |
Genentech Inc |
Polypeptide variants with altered effector function
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
WO2000060085A1
(en)
|
1999-04-02 |
2000-10-12 |
Millennium Pharmaceuticals, Inc. |
Fibroblast growth factor-20
|
|
US7390879B2
(en)
|
1999-06-15 |
2008-06-24 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US7129072B1
(en)
|
1999-08-30 |
2006-10-31 |
New York University |
Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
|
|
JP2001072607A
(ja)
|
1999-09-03 |
2001-03-21 |
Kyowa Hakko Kogyo Co Ltd |
新規血管内皮機能改善法
|
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
|
AU7368100A
(en)
|
1999-09-10 |
2001-04-10 |
Curagen Corporation |
Fibroblast growth factor polypeptide and nucleic acids encoding same
|
|
US6797695B1
(en)
|
1999-10-22 |
2004-09-28 |
Kyoto University |
Human FGF-20 gene and gene expression products
|
|
US6716626B1
(en)
|
1999-11-18 |
2004-04-06 |
Chiron Corporation |
Human FGF-21 nucleic acids
|
|
WO2001036640A2
(en)
|
1999-11-18 |
2001-05-25 |
Chiron Corporation |
Human fgf-21 gene and gene expression products
|
|
AU1415501A
(en)
|
1999-11-19 |
2001-06-04 |
Kyowa Hakko Kogyo Co. Ltd. |
Novel polypeptide, novel dna, novel anitbody and novel transgenic animal
|
|
DE10160151A1
(de)
|
2001-01-09 |
2003-06-26 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens
|
|
US20010044525A1
(en)
|
2000-01-05 |
2001-11-22 |
Conklin Darrell C. |
Novel FGF Homolog zFGF12
|
|
US20020081663A1
(en)
|
2000-01-05 |
2002-06-27 |
Conklin Darrell C. |
Novel FGF homolog ZFGF11
|
|
WO2001049849A1
(en)
|
2000-01-05 |
2001-07-12 |
Zymogenetics, Inc. |
Novel fgf homolog zfgf11
|
|
AU2759201A
(en)
|
2000-01-05 |
2001-07-16 |
Zymogenetics Inc. |
Novel fgf homolog zfgf12
|
|
US20060160181A1
(en)
|
2000-02-15 |
2006-07-20 |
Amgen Inc. |
Fibroblast Growth Factor-23 molecules and uses thereof
|
|
CA2398603A1
(en)
|
2000-02-15 |
2001-08-23 |
Amgen, Inc. |
Fibroblast growth factor-23 molecules and uses thereof
|
|
US20030180312A1
(en)
|
2000-02-22 |
2003-09-25 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
US20030105302A1
(en)
|
2000-03-08 |
2003-06-05 |
Nobuyuki Itoh |
Human FGF-23 gene and gene expression products
|
|
AU2001249125A1
(en)
|
2000-03-08 |
2001-09-17 |
Chiron Corporation |
Human fgf-23 gene and gene expression products
|
|
US20020001825A1
(en)
|
2000-03-31 |
2002-01-03 |
Nobuyuki Itoh |
Fibroblast growth factor-like molecules and uses thereof
|
|
US20030065140A1
(en)
|
2000-04-03 |
2003-04-03 |
Vernet Corine A.M. |
Novel proteins and nucleic acids encoding same
|
|
JP2002112772A
(ja)
|
2000-07-10 |
2002-04-16 |
Takeda Chem Ind Ltd |
新規ポリペプチドおよびそのｄｎａ
|
|
EP1303536B1
(en)
|
2000-07-19 |
2010-03-17 |
Advanced Research And Technology Institute, Inc. |
Novel fibroblast growth factor (fgf23) and methods for use
|
|
JP2004516013A
(ja)
|
2000-07-20 |
2004-06-03 |
ジェネンテック・インコーポレーテッド |
血管形成に関連する障害を診断及び治療するための組成物と方法
|
|
US20070037165A1
(en)
|
2000-09-08 |
2007-02-15 |
Applera Corporation |
Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
|
|
US6812339B1
(en)
|
2000-09-08 |
2004-11-02 |
Applera Corporation |
Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
|
|
US7265210B2
(en)
|
2000-09-15 |
2007-09-04 |
Genentech, Inc. |
Anti-PRO9821 antibodies
|
|
EP1197755A1
(en)
|
2000-10-11 |
2002-04-17 |
Pepscan Systems B.V. |
Identification of protein binding sites
|
|
US7537902B2
(en)
|
2000-10-24 |
2009-05-26 |
Emory University |
Methods and kits using a molecular interaction between a Smurf-1 WW domain and LIM mineralization protein isoforms
|
|
IL139380A0
(en)
|
2000-10-31 |
2001-11-25 |
Prochon Biotech Ltd |
Active variants of fibroblast growth factor
|
|
WO2002041911A2
(en)
|
2000-11-22 |
2002-05-30 |
Bayer Corporation |
Use of fgf-19 for inhibiting angiogenesis
|
|
US20020151496A1
(en)
|
2000-12-08 |
2002-10-17 |
Bringmann Peter W. |
Novel fibroblast growth factors
|
|
DE10100587C1
(de)
|
2001-01-09 |
2002-11-21 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Zielgens
|
|
DE10100588A1
(de)
|
2001-01-09 |
2002-07-18 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Zielgens
|
|
US7250495B2
(en)
|
2001-06-20 |
2007-07-31 |
Genentech, Inc. |
PRO20044 polypeptides
|
|
JP4578098B2
(ja)
|
2001-10-01 |
2010-11-10 |
ダイアックス、コープ |
多重鎖真核ディスプレイベクターとその使用
|
|
WO2003035842A2
(en)
|
2001-10-24 |
2003-05-01 |
Dyax Corporation |
Hybridization control of sequence variation
|
|
US20050107475A1
(en)
|
2002-03-21 |
2005-05-19 |
Jones Stacey A. |
Methods of using farnesoid x receptor (frx) agonists
|
|
US6987121B2
(en)
|
2002-04-25 |
2006-01-17 |
Smithkline Beecham Corporation |
Compositions and methods for hepatoprotection and treatment of cholestasis
|
|
JP2003334088A
(ja)
|
2002-05-22 |
2003-11-25 |
Pharma Design Inc |
ヒト由来の新規Ｋｌｏｔｈｏ様タンパク質及びその遺伝子
|
|
JP4753578B2
(ja)
|
2002-06-03 |
2011-08-24 |
ジェネンテック， インコーポレイテッド |
合成抗体ファージライブラリー
|
|
EP1553912A4
(en)
|
2002-06-07 |
2007-08-08 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
|
|
WO2004026228A2
(en)
|
2002-09-18 |
2004-04-01 |
Eli Lilly And Company |
Method for reducing morbidity and mortality in critically ill patients
|
|
WO2004063355A2
(en)
|
2003-01-10 |
2004-07-29 |
Protein Design Labs, Inc. |
Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
|
|
ES2298785T3
(es)
|
2003-06-12 |
2008-05-16 |
Eli Lilly And Company |
Proteinas de fusion.
|
|
WO2005044853A2
(en)
|
2003-11-01 |
2005-05-19 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
EA200601121A1
(ru)
|
2003-12-10 |
2006-10-27 |
Эли Лилли Энд Компани |
Мутеины фактора роста фибробластов 21
|
|
EP2194064A1
(en)
|
2004-05-13 |
2010-06-09 |
Eli Lilly & Company |
FGF-21 fusion proteins
|
|
JP2006016323A
(ja)
|
2004-06-30 |
2006-01-19 |
Hiroshima Industrial Promotion Organization |
生理活性バイオマテリアル
|
|
JP4809352B2
(ja)
|
2004-09-02 |
2011-11-09 |
イーライ リリー アンド カンパニー |
線維芽細胞成長因子２１の突然変異タンパク質
|
|
EP1789443A1
(en)
|
2004-09-02 |
2007-05-30 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
|
AU2005301152A1
(en)
|
2004-10-29 |
2006-05-11 |
Genentech, Inc. |
Disruptions of genes encoding secreted proteins, compositions and methods relating thereto
|
|
JP2008518610A
(ja)
|
2004-11-03 |
2008-06-05 |
アルマック ダイアグノスティックス リミテッド |
トランスクリプトームマイクロアレイ技法およびそれを使用する方法
|
|
JP2006158339A
(ja)
|
2004-12-09 |
2006-06-22 |
Kyoto Univ |
βＫｌｏｔｈｏ遺伝子、Ｃｙｐ７ａ１遺伝子、及びそれらの利用
|
|
EP1831371A2
(en)
|
2004-12-14 |
2007-09-12 |
Eli Lilly And Company |
Muteins of fibroblast growth factor 21
|
|
US20060275794A1
(en)
|
2005-03-07 |
2006-12-07 |
Invitrogen Corporation |
Collections of matched biological reagents and methods for identifying matched reagents
|
|
ATE450615T1
(de)
|
2005-07-22 |
2009-12-15 |
Five Prime Therapeutics Inc |
Zusammensetzungen und verfahren zur behandlung von krankheiten mit fgfr-fusionsproteinen
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
EP1929043A4
(en)
|
2005-08-24 |
2009-10-28 |
Genizon Biosciences Inc |
GENETIC CARD OF HUMAN GENES ASSOCIATED WITH CROHN'S DISEASE
|
|
WO2007091958A1
(en)
|
2006-02-10 |
2007-08-16 |
Dermagen Ab |
Novel antimicrobial peptides and use thereof
|
|
WO2008021196A2
(en)
|
2006-08-09 |
2008-02-21 |
The Mclean Hospital Corporation |
Methods and compositions for the treatment of medical disorders
|
|
CN101563597A
(zh)
|
2006-09-01 |
2009-10-21 |
美国菌种保藏中心 |
用于诊断和治疗2型糖尿病的组合物和方法
|
|
WO2008052796A1
(en)
|
2006-11-03 |
2008-05-08 |
U3 Pharma Gmbh |
Fgfr4 antibodies
|
|
WO2008085879A2
(en)
|
2007-01-03 |
2008-07-17 |
California Stem Cell, Inc. |
Stem cell growth media and methods of making and using same
|
|
CN107501407B
(zh)
|
2007-03-30 |
2022-03-18 |
Ambrx公司 |
经修饰fgf-21多肽和其用途
|
|
EP2550972B1
(en)
|
2007-04-02 |
2018-02-21 |
Genentech, Inc. |
A Klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
|
|
WO2008123625A1
(ja)
|
2007-04-06 |
2008-10-16 |
National Institute Of Advanced Industrial Science And Technology |
補助因子による受容体の活性化方法並びにリガンド活性の利用方法
|
|
US10555963B2
(en)
|
2007-05-08 |
2020-02-11 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Klotho protein and related compounds for the treatment and diagnosis of cancer
|
|
WO2008135993A1
(en)
|
2007-05-08 |
2008-11-13 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Klotho protein and related compounds for the treatment and diagnosis of cancer
|
|
EP2036539A1
(en)
|
2007-09-11 |
2009-03-18 |
Novo Nordisk A/S |
Stable formulations of amylin and its analogues
|
|
WO2009076478A2
(en)
|
2007-12-10 |
2009-06-18 |
The Johns Hopkins University |
Hypomethylated genes in cancer
|
|
EP2080812A1
(en)
|
2008-01-18 |
2009-07-22 |
Transmedi SA |
Compositions and methods of detecting post-stop peptides
|
|
TW200936156A
(en)
|
2008-01-28 |
2009-09-01 |
Novartis Ag |
Methods and compositions using Klotho-FGF fusion polypeptides
|
|
US8420088B2
(en)
|
2008-01-28 |
2013-04-16 |
Novartis Ag |
Methods and compositions using FGF23 fusion polypeptides
|
|
US20090226459A1
(en)
|
2008-01-29 |
2009-09-10 |
Cold Spring Harbor Laboratory |
Role of fgf-19 in cancer diagnosis and treatment
|
|
NZ602702A
(en)
|
2008-03-19 |
2014-03-28 |
Ambrx Inc |
Modified fgf-21 polypeptides and their uses
|
|
WO2009117622A2
(en)
|
2008-03-19 |
2009-09-24 |
Ambrx, Inc. |
Modified fgf-23 polypeptides and their uses
|
|
CA2719001A1
(en)
|
2008-03-21 |
2009-09-24 |
Podiceps B.V. |
Diagnostic of pre-symptomatic metabolic syndrome
|
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
|
FR2933702A1
(fr)
|
2008-07-08 |
2010-01-15 |
Sanofi Aventis |
Antagonistes specifiques du recepteur fgf-r4
|
|
WO2010006214A1
(en)
|
2008-07-09 |
2010-01-14 |
Ambrx, Inc. |
Fgf-21 neutralizing antibodies and their uses
|
|
JP5787757B2
(ja)
|
2008-08-04 |
2015-09-30 |
ファイブ プライム セラピューティックス インコーポレイテッド |
Ｆｇｆｒ細胞外ドメイン酸性領域突然変異タンパク質
|
|
JP5878757B2
(ja)
|
2008-10-10 |
2016-03-08 |
アムジエン・インコーポレーテツド |
Ｆｇｆ２１変異体およびその使用
|
|
WO2010065439A1
(en)
|
2008-12-05 |
2010-06-10 |
Eli Lilly And Company |
Variants of fibroblast growth factor 21
|
|
US20120035105A1
(en)
|
2009-01-09 |
2012-02-09 |
Sdg, Inc. |
Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
|
|
US20100274362A1
(en)
|
2009-01-15 |
2010-10-28 |
Avner Yayon |
Cartilage particle tissue mixtures optionally combined with a cancellous construct
|
|
KR101544245B1
(ko)
|
2009-02-03 |
2015-08-12 |
아뮤닉스 오퍼레이팅 인코포레이티드 |
연장된 재조합 폴리펩티드 및 이를 포함하는 조성물
|
|
BRPI1011404B1
(pt)
|
2009-05-05 |
2022-05-03 |
Amgen Inc |
Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
|
|
JP2012525847A
(ja)
|
2009-05-05 |
2012-10-25 |
アムジエン・インコーポレーテツド |
Ｆｇｆ２１変異体およびその使用
|
|
US8461111B2
(en)
|
2009-05-20 |
2013-06-11 |
Florida State University Research Foundation |
Fibroblast growth factor mutants having improved functional half-life and methods of their use
|
|
EP2437775A1
(en)
|
2009-06-04 |
2012-04-11 |
Novartis AG |
Fgf-21 for treating cancers
|
|
JP2012529463A
(ja)
|
2009-06-11 |
2012-11-22 |
ノヴォ ノルディスク アー／エス |
２型糖尿病を治療するための、ｇｌｐ−１とｆｇｆ２１との組合せ
|
|
US8324160B2
(en)
|
2009-06-17 |
2012-12-04 |
Amgen Inc. |
Chimeric polypeptides and uses thereof
|
|
CN101993485B
(zh)
|
2009-08-20 |
2013-04-17 |
重庆富进生物医药有限公司 |
促胰岛素分泌肽类似物同源二聚体及其用途
|
|
RU2573896C2
(ru)
|
2009-10-15 |
2016-01-27 |
Дженентек, Инк. |
Химерные факторы роста фибробластов с измененной рецепторной специфичностью
|
|
US8889621B2
(en)
|
2009-10-30 |
2014-11-18 |
New York University |
Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
|
|
SG177025A1
(en)
*
|
2010-06-21 |
2012-01-30 |
Agency Science Tech & Res |
Hepatitis b virus specific antibody and uses thereof
|
|
JP2013512672A
(ja)
|
2009-12-02 |
2013-04-18 |
アムジエン・インコーポレーテツド |
ヒトＦＧＦＲ１ｃ、ヒトβ−クロト−、ならびにヒトＦＧＦＲ１ｃおよびヒトβ−クロト−の両方に結合する結合タンパク質
|
|
WO2011084808A2
(en)
|
2009-12-21 |
2011-07-14 |
Amunix Operating Inc. |
Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
|
|
EP2460527A1
(en)
|
2010-01-21 |
2012-06-06 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
US20110195077A1
(en)
|
2010-01-29 |
2011-08-11 |
Novartis Ag |
Methods and compositions using fgf23 fusion ppolypeptides
|
|
MX2012011986A
(es)
|
2010-04-15 |
2013-03-05 |
Amgen Inc |
RECEPTOR FGF HUMANO Y PROTEINAS ENLAZADAS A ß-KLOTHO.
|
|
JP5767314B2
(ja)
|
2010-04-16 |
2015-08-19 |
ソーク インスティチュート フォー バイオロジカル スタディーズ |
Ｆｇｆを用いて代謝障害を処置するための方法
|
|
JP2013533227A
(ja)
|
2010-06-08 |
2013-08-22 |
ノヴォ ノルディスク アー／エス |
Ｆｇｆ２１類似体および誘導体
|
|
US9655974B2
(en)
|
2010-07-20 |
2017-05-23 |
Novo Nordisk A/S |
N-terminal modified FGF21 compounds
|
|
RU2013115747A
(ru)
|
2010-09-09 |
2014-10-20 |
ТРИФОЙЛИУМ АпС |
Введение антиангиогенных агентов в дыхательные пути
|
|
MX360946B
(es)
|
2010-09-22 |
2018-10-29 |
Amgen Inc Star |
Inmunoglobulinas portadoras y usos de las mismas.
|
|
CN102464712A
(zh)
|
2010-11-11 |
2012-05-23 |
重庆富进生物医药有限公司 |
缺失型人成纤维细胞生长因子21变异体及其偶联物
|
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
|
KR20140020851A
(ko)
|
2010-12-22 |
2014-02-19 |
마르카디아 바이오테크, 인코퍼레이트 |
Gip 및 glp-1 수용체-활성 글루카곤계 펩타이드를 이용한 대사장애 및 비만의 치료방법
|
|
WO2012086809A1
(ja)
|
2010-12-24 |
2012-06-28 |
独立行政法人産業技術総合研究所 |
ヒトfgf19活性の正確で高感度な測定方法ならびにヒトfgf19活性の制御剤
|
|
AU2012240102C1
(en)
|
2011-04-08 |
2016-09-08 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
|
|
WO2012140650A2
(en)
|
2011-04-12 |
2012-10-18 |
Hepacore Ltd. |
Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
|
|
US20140189893A1
(en)
|
2011-05-10 |
2014-07-03 |
Amgen Inc. |
Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta klotho
|
|
DK2710035T3
(en)
|
2011-05-16 |
2017-06-19 |
Hoffmann La Roche |
FGFR1 agonists and methods of use
|
|
CN103649386B
(zh)
|
2011-06-08 |
2015-12-23 |
索元生物医药（杭州）有限公司 |
预测类视黄醇x受体调节剂活性的方法和组合物
|
|
WO2012177481A2
(en)
|
2011-06-24 |
2012-12-27 |
University Of Miami |
Fibroblast growth factor receptor inhibition for the treatment of disease
|
|
HUE045629T2
(hu)
|
2011-07-01 |
2020-01-28 |
Ngm Biopharmaceuticals Inc |
Készítmények, alkalmazások és eljárások anyagcsere rendellenességek és betegségek kezelésére
|
|
EP2548570A1
(en)
|
2011-07-19 |
2013-01-23 |
Sanofi |
Pharmaceutical composition for treating a metabolic syndrome
|
|
WO2013027191A1
(en)
|
2011-08-25 |
2013-02-28 |
Novartis Ag |
Methods and compositions using fgf23 fusion polypeptides
|
|
CA2845357A1
(en)
|
2011-08-31 |
2013-03-07 |
Amgen Inc. |
Method of treating or ameliorating type 1 diabetes using fgf21
|
|
UY34347A
(es)
|
2011-09-26 |
2013-04-30 |
Novartis Ag |
Proteínas de función dual para tratar trastornos metabólicos
|
|
US9006400B2
(en)
|
2011-09-26 |
2015-04-14 |
Novartis Ag |
Fibroblast growth factor-21-Fc fusion proteins
|
|
AR087973A1
(es)
|
2011-10-04 |
2014-04-30 |
Lilly Co Eli |
Variantes del factor 21 del crecimiento de fibroblastos
|
|
SG11201401699WA
(en)
|
2011-11-11 |
2014-09-26 |
Rinat Neuroscience Corp |
Antibodies specific for trop-2 and their uses
|
|
MX2014008699A
(es)
|
2012-01-18 |
2014-11-21 |
Genentech Inc |
Metodos para utilizar moduladores de fgf19.
|
|
WO2013131091A1
(en)
|
2012-03-02 |
2013-09-06 |
New York University |
Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity and related metabolic disorders
|
|
JP2013194049A
(ja)
|
2012-03-23 |
2013-09-30 |
Kazuo Todokoro |
ヒト造血幹細胞を増幅させるための組成物及び方法
|
|
EP3520821A1
(en)
|
2012-04-02 |
2019-08-07 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
|
EP2844273B1
(en)
|
2012-04-16 |
2018-01-31 |
Tel HaShomer Medical Research Infrastructure and Services Ltd. |
Klotho variant polypeptides and uses thereof in therapy
|
|
KR20150002801A
(ko)
|
2012-05-15 |
2015-01-07 |
일라이 릴리 앤드 캄파니 |
섬유모세포 성장 인자 21 단백질의 치료 용도
|
|
US9474785B2
(en)
|
2012-06-07 |
2016-10-25 |
New York University |
Chimeric fibroblast growth factor 19 proteins and methods of use
|
|
US9657075B2
(en)
|
2012-06-07 |
2017-05-23 |
New York University |
Chimeric fibroblast growth factor 23 proteins and methods of use
|
|
US9464126B2
(en)
|
2012-06-07 |
2016-10-11 |
New York University |
Chimeric fibroblast growth factor 21 proteins and methods of use
|
|
TWI513705B
(zh)
|
2012-06-11 |
2015-12-21 |
Lilly Co Eli |
纖維母細胞生長因子２１蛋白質
|
|
JP6181752B2
(ja)
|
2012-06-11 |
2017-08-16 |
イーライ リリー アンド カンパニー |
線維芽細胞増殖因子２１変異体
|
|
BR112015000653A2
(pt)
|
2012-07-11 |
2019-11-05 |
Blueprint Medicines Corp |
compostos inibidores do receptor de fator de crescimento de fibroblasto, sua composição farmacêutica e seus usos
|
|
AR092076A1
(es)
|
2012-08-22 |
2015-03-18 |
Lilly Co Eli |
Proteinas homodimericas
|
|
SG11201500682WA
(en)
|
2012-09-07 |
2015-02-27 |
Sanofi Sa |
Fusion proteins for treating a metabolic syndrome
|
|
CA2892152A1
(en)
|
2012-11-28 |
2014-06-05 |
Ngm Biopharmaceuticals, Inc. |
Compositions and methods for treatment of metabolic disorders and diseases
|
|
US9290557B2
(en)
|
2012-11-28 |
2016-03-22 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants and fusions of FGF19 polypeptides
|
|
SG10202100667SA
(en)
|
2012-12-27 |
2021-02-25 |
Ngm Biopharmaceuticals Inc |
Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
US9273107B2
(en)
|
2012-12-27 |
2016-03-01 |
Ngm Biopharmaceuticals, Inc. |
Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
WO2014130659A1
(en)
|
2013-02-22 |
2014-08-28 |
New York University |
Chimeric fibroblast growth factor 23 proteins and methods of use
|
|
WO2014152090A1
(en)
|
2013-03-14 |
2014-09-25 |
Georgetown University |
Compositions and treatments of metabolic disorders using fgf binding protein 3 and fgf 19
|
|
WO2014149699A1
(en)
|
2013-03-15 |
2014-09-25 |
Eli Lilly And Company |
Bifunctional protein
|
|
CA2928135A1
(en)
|
2013-10-21 |
2015-04-30 |
Salk Institute For Biological Studies |
Mutated fibroblast growth factor (fgf) 1 and methods of use
|
|
RU2707531C2
(ru)
|
2013-10-28 |
2019-11-27 |
ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. |
Модели рака и соответствующие способы
|
|
TWI728373B
(zh)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
抗體及使用方法
|
|
KR102489475B1
(ko)
|
2014-01-24 |
2023-01-20 |
엔지엠 바이오파마슈티컬스, 아이엔씨. |
결합 단백질 및 그의 사용 방법
|
|
US10398758B2
(en)
|
2014-05-28 |
2019-09-03 |
Ngm Biopharmaceuticals, Inc. |
Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
|
|
US10456449B2
(en)
|
2014-06-16 |
2019-10-29 |
Ngm Biopharmaceuticals, Inc. |
Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
|
|
RU2729161C2
(ru)
|
2014-10-23 |
2020-08-04 |
ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. |
Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
|
|
WO2016073855A1
(en)
|
2014-11-07 |
2016-05-12 |
Ngm Biopharmaceuticals, Inc. |
Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
|
|
WO2017019957A2
(en)
|
2015-07-29 |
2017-02-02 |
Ngm Biopharmaceuticals, Inc. |
Binding proteins and methods of use thereof
|
|
ES2871036T3
(es)
|
2015-11-09 |
2021-10-28 |
Ngm Biopharmaceuticals Inc |
Método para el tratamiento de trastornos relacionados con ácidos biliares
|
|
AU2017315459B2
(en)
|
2016-08-26 |
2023-06-29 |
Ngm Biopharmaceuticals, Inc. |
Methods of treating fibroblast growth factor 19-mediated cancers and tumors
|
|
CA3034435A1
(en)
|
2016-08-29 |
2018-03-08 |
Lei Ling |
Methods for treatment of bile acid-related disorders
|
